NFKB1 and prostate carcinoma: In addition to the studies on the expression of NF-κB in human PACs discussed above, there are data using interleukin(IL)-6 as a surrogate marker of NF-κB activation in patients with prostate cancer that further suggest a role of NF-κB in a clinical setting (Zerbini et al, 2003).